Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,630 signal articles · 39 in last 24h · 155,690 total before filter · latest 54m ago
39last 24h
849last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings106M&A123Regulatory20Product21Analyst19
Sentiment:bullishneutralbearishshow all (incl. clickbait)
Wealth Management Stocks Fall After Vanguard Aquires Tech Platform
The Wall Street Journal31d agobearish
Wealth Management Stocks Fall After Vanguard Aquires Tech Platform

Vanguard's ambition to expand in financial advice is causing some trepidation among investors in the industry's incumbents. Shares of Charles Schwab and LPL Financial were off more than 2% in morning trading Wednesday after Vanguard announced the acquisition of Altruist, a fintech wealth management platform. Altruist competes with Schwab to custody assets on behalf of financial advisers, and offers AI tools for tax and financial planning.

Zoom Falls 6% as Soft Q3 Profit Guidance Overshadows a Double Beat; HubSpot and Monday.com Slip
24/7 Wall St.31d agobearish
Zoom Falls 6% as Soft Q3 Profit Guidance Overshadows a Double Beat; HubSpot and Monday.com Slip

A soft third-quarter profit outlook is overshadowing an otherwise clean beat at Zoom Communications (NASDAQ:ZM), sending the video collaboration name lower even as the broader software tape barely moves. Zoom stock is down 6% to $95.08 Wednesday morning after the company delivered a Q2 FY2027 double beat, raised its full-year outlook, and then guided Q3 ... Zoom Falls 6% as Soft Q3 Profit Guidance Overshadows a Double Beat; HubSpot and Monday.com Slip

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
Benzinga31d agoneutral
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

Abercrombie & Fitch raises full-year outlook as Q2 earnings top estimates
Proactive31d agoneutral
Abercrombie & Fitch raises full-year outlook as Q2 earnings top estimates

Abercrombie & Fitch (NYSE:ANF) shares rose about 13% on Wednesday after the apparel retailer reported second quarter fiscal 2026 results that exceeded Wall Street expectations and raised its full-year outlook. The company reported adjusted earnings per diluted share of $4.17, compared...

Bond Selloff Resumes After July Inflation Data
Barrons.com31d agobearish
Bond Selloff Resumes After July Inflation Data

The Fed’s closely-watched inflation gauge revealed prices were a bit higher than expected in July--bond traders don't like that. After taking a breather on Tuesday, bonds are selling off yet again. Yield were up across the board on Wednesday morning; both the 2-year and 10-year yield were up by around 0.